WNK2 and neoplasm: Sorafenib works as a multitarget kinase inhibitor, which blocks important pathways including Raf (the rapidly accelerated fibrosarcoma)/mitogen-activated protein kinase, c-Kit, vascular endothelial growth factor receptor and platelet-derived growth factor receptor, leading to decreased tumor angiogenesis, tumor cell proliferation, and increased tumor cell apoptosis (4).